Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate


Product Details

CAT No.# CS-T-16449
Category Impurities
CAS 1408238-36-7
Molecular Weight 479.57
Molecular Formula C26H33N5O4
Purity: >98%
Synonyms: 2-[[[4-[[[(Hexylo]amino]methyl]-1-methyl-1H-benzimidazoleEthyl Ester,Dabigatran Impurity
Application Notes: Des-(N-2-pyridyl-Beta-alanine ethyl ester) Dabigatran etexilate 5-ethyl carboxylate is a derivative of Dabigatran , an oral thrombin inhibitor used to prevent venous thromboembolism. ;Impurity in commercial preparations of Dabigatran
References: Eerenberg, E., et al.: Circulation, 124, 1573 (2011); Eriksson, B., et al.: Lancet, 370, 949 (2007); van Ryn, J., et al.: Thromb. & Haemo., 103, 1116 (2010)
COA / MSDS:    View COA    MSDS    Enquire
The balance used are calibrated with weights traceable to National Standards NIST for accuracy
Related Results for 'Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate'

- API Standards of Dabigatran
- Stable Isotopes of Dabigatran
- Metabolites of Dabigatran
- Impurities of Dabigatran
- Glucuronides of Dabigatran
- Intermediates of Dabigatran

PEOPLE ALSO SEARCHED FOR: 1. (6R,7S)-7-(2-chloroacetamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
2. propan-2-yl-5-hydroxy-2-methyl-2-4-(3-nitrophenyl)-6-oxo-1,4,5,5-tetraahydropyridine-3-carboxylate
3. ([13C6]Leu5)-Ghrelin (human) (H-7252.1000)
4. Benidipine D7
5. Lauroside D
6. Triazolam 13C D3
7. Icatibant impurity 1
9. 0.1% TFA in Water ULC-MS
10. Metamizole EP Impurity C HCl
11. Silodosin Metabolite D4
12. Brivaracetam Carboxylic acid metabolite [UCB 42145]
13. Terbuthylazine D5
14. tibolone (848)
15. (Z)-Dimethylvinphos
16. Silodosin Metabolite
17. 2-Phenoxymethanesulfonanilide
18. Nimesulide EP Impurity A
19. Acetone HPLC
20. Nandrolone Decanoate EP impurity F

This page contains information about Des-(N-2-pyridyl-β-alanine Ethyl Ester) Dabigatran Etexilate 5-Ethyl Carboxylate Cas 1408238-36-7 and its Impurities.
"Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk."